Current progress and future direction of hemophilia treatment
Current progress and future direction of hemophilia treatment
复制标题
血友病治疗的现状及未来方向
DOI：
10.11406/rinketsu.56.2100
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
松下正
中科院分区：
文献类型：
--
作者：
Yoshioka A;Ishii E;Ueno T;Usami I;Kobayashi M;Kobayashi R;Sotomatsu M;Shirahata A;Suzuki T;Taki M;Ishida Y;Matsushita T;Shima M;Nogami K;Sakai M;Kigasawa H;Fukutake K;松下正
血友病是一种罕见的出血性疾病，治疗方法仍在开发中，几种新药物正在为患者提供更好的生活质量。JSTH已经发布了基于证据和/或实践的国家指南。为血友病止血治疗提供的建议有助于医疗保健提供者启动一般血友病护理。本文首先回顾了两个国家指南的患者与/无抑制剂治疗。最后，对目前治疗的进展以及新的药物进行了总结。预计在不久的将来，将向日本的所有护理人员提出治疗方案。
Hemophilia is a rare bleeding disorder, for which treatments are still being developing and several new agents are providing better quality of life for patents. National evidence-and/or practice-based guidelines have been published by JSTH. Recommendations offered for the hemostatic management of hemophilia have assisted healthcare providers in initiating general hemophilia care. This article first reviews the two national guidelines for patients with/without inhibitor treatments. Then, future perspectives on progress in current treatment as well as the newer agents are summarized. Treatment options anticipated to be available in the near future are proposed for all caregivers in Japan.